Selected research
Industry Research
Quetiapine Fumarate Sustained Release Tablets Industry Research Report 2026
Market perspective
The global Quetiapine Fumarate Sustained Release Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Quetiapine Fumarate Sustained Release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Quetiapine Fumarate Sustained Release Tablets market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Quetiapine Fumarate Sustained Release Tablets market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Quetiapine Fumarate Sustained Release Tablets include Dr. Reddy's Laboratories, Lupin Limited, Luye Pharma Limited, PHARMATHEN INVESTMENTS GROUP LIMITED, Seroquel, Torrent Pharmaceuticals, Mylan N.V., Sandoz and Sun Pharmaceutical Industries and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Quetiapine Fumarate Sustained Release Tablets market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Quetiapine Fumarate Sustained Release Tablets.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Quetiapine Fumarate Sustained Release Tablets Market by Company
Dr. Reddy's Laboratories
Lupin Limited
Luye Pharma Limited
PHARMATHEN INVESTMENTS GROUP LIMITED
Seroquel
Torrent Pharmaceuticals
Mylan N.V.
Sandoz
Sun Pharmaceutical Industries
Teva Pharmaceutical Industries
Quetiapine Fumarate Sustained Release Tablets Segment by Type
50mg
200mg
300mg
400mg
Quetiapine Fumarate Sustained Release Tablets Segment by Application
Hospital
Clinic
Others
Quetiapine Fumarate Sustained Release Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quetiapine Fumarate Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Quetiapine Fumarate Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quetiapine Fumarate Sustained Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Quetiapine Fumarate Sustained Release Tablets companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg
- 200mg
- 300mg
- 400mg
Applications
- Hospital
- Clinic
- Others
Companies covered
- Dr. Reddy's Laboratories
- Lupin Limited
- Luye Pharma Limited
- PHARMATHEN INVESTMENTS GROUP LIMITED
- Seroquel
- Torrent Pharmaceuticals
- Mylan N.V.
- Sandoz
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Quetiapine Fumarate Sustained Release Tablets by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 50mg
- 2.2.3 200mg
- 2.2.4 300mg
- 2.2.5 400mg
- 2.3 Quetiapine Fumarate Sustained Release Tablets by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Quetiapine Fumarate Sustained Release Tablets Breakdown Data by Type
- 3.1 Global Quetiapine Fumarate Sustained Release Tablets Historic Market Size by Type (2021-2026)
- 3.2 Global Quetiapine Fumarate Sustained Release Tablets Forecasted Market Size by Type (2027-2032)
4 Quetiapine Fumarate Sustained Release Tablets Breakdown Data by Application
- 4.1 Global Quetiapine Fumarate Sustained Release Tablets Historic Market Size by Application (2021-2026)
- 4.2 Global Quetiapine Fumarate Sustained Release Tablets Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Quetiapine Fumarate Sustained Release Tablets Market Perspective (2021-2032)
- 5.2 Global Quetiapine Fumarate Sustained Release Tablets Growth Trends by Region
- 5.2.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Quetiapine Fumarate Sustained Release Tablets Historic Market Size by Region (2021-2026)
- 5.2.3 Quetiapine Fumarate Sustained Release Tablets Forecasted Market Size by Region (2027-2032)
- 5.3 Quetiapine Fumarate Sustained Release Tablets Market Dynamics
- 5.3.1 Quetiapine Fumarate Sustained Release Tablets Industry Trends
- 5.3.2 Quetiapine Fumarate Sustained Release Tablets Market Drivers
- 5.3.3 Quetiapine Fumarate Sustained Release Tablets Market Challenges
- 5.3.4 Quetiapine Fumarate Sustained Release Tablets Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Quetiapine Fumarate Sustained Release Tablets Players by Revenue
- 6.1.1 Global Top Quetiapine Fumarate Sustained Release Tablets Players by Revenue (2021-2026)
- 6.1.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Players (2021-2026)
- 6.2 Global Quetiapine Fumarate Sustained Release Tablets Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Quetiapine Fumarate Sustained Release Tablets Head Office and Area Served
- 6.4 Global Quetiapine Fumarate Sustained Release Tablets Players, Product Type & Application
- 6.5 Global Quetiapine Fumarate Sustained Release Tablets Manufacturers Established Date
- 6.6 Global Quetiapine Fumarate Sustained Release Tablets Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 7.2 North America Quetiapine Fumarate Sustained Release Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 7.4 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 8.2 Europe Quetiapine Fumarate Sustained Release Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 8.4 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 9.2 Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 10.2 South America Quetiapine Fumarate Sustained Release Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 10.4 South America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 11.2 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Dr. Reddy's Laboratories
- 12.1.1 Dr. Reddy's Laboratories Company Information
- 12.1.2 Dr. Reddy's Laboratories Business Overview
- 12.1.3 Dr. Reddy's Laboratories Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.1.4 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.1.5 Dr. Reddy's Laboratories Recent Developments
- 12.2 Lupin Limited
- 12.2.1 Lupin Limited Company Information
- 12.2.2 Lupin Limited Business Overview
- 12.2.3 Lupin Limited Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.2.4 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.2.5 Lupin Limited Recent Developments
- 12.3 Luye Pharma Limited
- 12.3.1 Luye Pharma Limited Company Information
- 12.3.2 Luye Pharma Limited Business Overview
- 12.3.3 Luye Pharma Limited Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.3.4 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.3.5 Luye Pharma Limited Recent Developments
- 12.4 PHARMATHEN INVESTMENTS GROUP LIMITED
- 12.4.1 PHARMATHEN INVESTMENTS GROUP LIMITED Company Information
- 12.4.2 PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview
- 12.4.3 PHARMATHEN INVESTMENTS GROUP LIMITED Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.4.4 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.4.5 PHARMATHEN INVESTMENTS GROUP LIMITED Recent Developments
- 12.5 Seroquel
- 12.5.1 Seroquel Company Information
- 12.5.2 Seroquel Business Overview
- 12.5.3 Seroquel Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.5.4 Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.5.5 Seroquel Recent Developments
- 12.6 Torrent Pharmaceuticals
- 12.6.1 Torrent Pharmaceuticals Company Information
- 12.6.2 Torrent Pharmaceuticals Business Overview
- 12.6.3 Torrent Pharmaceuticals Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.6.4 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.6.5 Torrent Pharmaceuticals Recent Developments
- 12.7 Mylan N.V.
- 12.7.1 Mylan N.V. Company Information
- 12.7.2 Mylan N.V. Business Overview
- 12.7.3 Mylan N.V. Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.7.4 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.7.5 Mylan N.V. Recent Developments
- 12.8 Sandoz
- 12.8.1 Sandoz Company Information
- 12.8.2 Sandoz Business Overview
- 12.8.3 Sandoz Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.8.4 Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.8.5 Sandoz Recent Developments
- 12.9 Sun Pharmaceutical Industries
- 12.9.1 Sun Pharmaceutical Industries Company Information
- 12.9.2 Sun Pharmaceutical Industries Business Overview
- 12.9.3 Sun Pharmaceutical Industries Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.9.4 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.9.5 Sun Pharmaceutical Industries Recent Developments
- 12.10 Teva Pharmaceutical Industries
- 12.10.1 Teva Pharmaceutical Industries Company Information
- 12.10.2 Teva Pharmaceutical Industries Business Overview
- 12.10.3 Teva Pharmaceutical Industries Revenue in Quetiapine Fumarate Sustained Release Tablets Business (2021-2026)
- 12.10.4 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 12.10.5 Teva Pharmaceutical Industries Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst